Beta Bionics, Inc. $BBNX Position Boosted by Pura Vida Investments LLC

Key Points

• Pura Vida Investments increased its stake in Beta Bionics by 11,150% in Q3 to 281,250 shares, making BBNX the fund’s largest holding (36.1% of its portfolio) and representing about $5.59 million or ~0.64% of the company.
• A recent wave of insider selling (34,352 shares, ~$941K in the last three months, including sales by the CFO) plus a shareholder investigation notice from Faruqi & Faruqi raise near‑term legal and sentiment risk.
• Beta Bionics beat EPS estimates (‑$0.30 vs. ‑$0.42) and holds a consensus "Moderate Buy" with a $23.20 average target, yet the stock trades near $11.38, well below its 50‑day ($18.35) and 200‑day ($22.35) moving averages.

Pura Vida Investments LLC increased its stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) by 11,150.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 281,250 shares of the company's stock after acquiring an additional 278,750 shares during the quarter. Beta Bionics comprises about 36.1% of Pura Vida Investments LLC's portfolio, making the stock its largest holding. Pura Vida Investments LLC owned approximately 0.64% of Beta Bionics worth $5,588,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of BBNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Beta Bionics in the 1st quarter valued at $95,000. Goldman Sachs Group Inc. bought a new position in shares of Beta Bionics during the 1st quarter valued at about $715,000. Woodline Partners LP purchased a new position in shares of Beta Bionics during the first quarter valued at about $1,530,000. Strs Ohio bought a new stake in shares of Beta Bionics in the first quarter worth about $29,000. Finally, Rhumbline Advisers purchased a new stake in shares of Beta Bionics in the first quarter worth about $158,000.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Recent operational/analyst context supports longer‑term upside — Beta Bionics beat EPS estimates in its Feb. 17 quarter and the consensus analyst view remains a "Moderate Buy" with a $23.20 average price target, providing a counterbalance to near‑term selling. MarketBeat coverage
• Neutral Sentiment: Short‑interest data published for early March shows implausible values (entries report "0 shares"/NaN and 0.0 days to cover), so there is no reliable signal from short sellers — treat reported short‑interest changes as inconclusive until corrected by exchanges or data providers.
• Negative Sentiment: A wave of small insider sell orders was disclosed in early March (including the CFO’s sale of 1,428 shares and several other executive sales at roughly $12.36 each). Multiple Form 4 filings and press coverage frame this as coordinated executive selling, which often pressures sentiment for small‑cap biotech/medical device stocks. TipRanks: Insiders Cash Out
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice seeking investors who experienced losses, increasing legal and reputational risk and likely weighing on near‑term sentiment until the matter is clarified. GlobeNewswire: Faruqi & Faruqi notice

Analyst Upgrades and Downgrades

BBNX has been the subject of several research analyst reports. Lake Street Capital set a $20.00 price target on Beta Bionics in a report on Wednesday, February 18th. Wall Street Zen downgraded Beta Bionics from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. Robert W. Baird reduced their price target on shares of Beta Bionics from $28.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 18th. Stifel Nicolaus decreased their price target on shares of Beta Bionics from $25.00 to $22.00 and set a "buy" rating on the stock in a research note on Wednesday, February 18th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $25.00 price objective on shares of Beta Bionics in a research note on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $23.20.

Beta Bionics Stock Performance

Shares of Beta Bionics stock opened at $11.38 on Thursday. The stock has a market cap of $505.04 million, a price-to-earnings ratio of -5.84 and a beta of 5.60. The stock has a 50 day moving average price of $18.35 and a 200-day moving average price of $22.35. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.12. The company had revenue of $32.12 million for the quarter. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.

Insider Buying and Selling at Beta Bionics

In related news, insider Mike Mensinger sold 2,200 shares of the company's stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total transaction of $66,220.00. Following the transaction, the insider directly owned 80,752 shares in the company, valued at approximately $2,430,635.20. This represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares in the company, valued at $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 34,352 shares of company stock worth $941,569.

Beta Bionics Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.